




PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/807,506		
		Filing Date	April 13, 2001		
		First Named Inventor	Marta Blumenfeld		
		Art Unit	1634		
		Examiner Name	Unknown <i>Goldberg</i>		
Sheet	1	of	1	Attorney Docket Number	G-050US03PCT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 00/22122 A3	04/20/2000	Genset	_____	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature	<i>JS Goldberg</i>	Date Considered	7/2/03
--------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED
MAY 16 2002
TECH CENTER 1600/2900

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/807,506		
		Filing Date	Int.Apl.:10/10/1999 (08/06/2001)		
		First Named Inventor	Blumenfeld, et al.		
		Art Unit	1645		
		Examiner Name	Unassigned		
Sheet	1	of	5	Attorney Docket Number	50.US3.PCT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
88	A	US- 6,291,182 - B1	09/18/2001	Schork, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code 3 - Number 4 - Kind Code 5 (if known)				
88	B	WO 98/11222 - A1	03/19/1998	Mt. Sinai School of Med.		
	C	WO 01/40493 - A2	06/07/2001	Genset		

Examiner Signature	<i>J. Goldberg</i>	Date Considered	1/7/03
--------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/807,506		
		Filing Date	Int.Apl.:10/10/1999 (08/06/2001)		
		First Named Inventor	Blumenfeld, et al.		
		Group Art Unit	1645		
		Examiner Name	Unassigned		
Sheet	3	of	5	Attorney Docket Number	50.US3.PCT

RECEIVED
MAY 16 2002
TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
JG	O	LIN, ET AL.; "Suggestive evidence for linkage of schizophrenia to markers on chromosome 13 in Caucasian but not Oriental populations"; Hum Genet (1997) 99:417-420; Springer-Verlag 1997	
	P	KELSOE, ET AL.; "A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22"; PNAS; January 16, 2001; Vol. 98, No. 2, pp. 585-590; www.pnas.org	
	Q	CIMATO, ET AL.; "Nerve growth factor-specific regulation of protein methylation during neuronal differentiation of PC12 Cells"; The Rockefeller University Press, 0021-9525/97/09/1089/15; The Journal of Cell Biology, Vol. 138, No. 5, September 8, 1997; pgs. 1089-1103; http://www.jcb.org	
	R	BASSETT; ET AL.; "Evidence for anticipation in schizophrenia"; Am. J. Hum. Genet. 54:864-870, 1994; The American Society of Human Genetics; 0002-9297/94/5405-0016	
	S	McINNIS, ET AL.; "Anticipation in bipolar affective disorder"; Am. J. Hum. Genet. 53:385-390, 1993; The American Society of Human Genetics; 0002-9297/93/5302-0010	
	T	ZONANA, ET AL.; "X-linked Hypohidrotic Ectodermal Dysplasia: localization within the region Xq11-21.1 by Linkage Analysis and Implications for Carrier Detection and Prenatal Diagnosis"; Am. J. Hum. Genet. 43:075-085, 1988; The American Society of Human Genetics; 0002-9297/99/4301-0011	
	U	Accession: AF087142; Zonana, et al.; "Isolation and characterization of a human X-linked gene mapping to the Xq13.1 region"; Unpublished	
	V	FIRESTEIN, ET AL.; "Cypin: a cytosolic regulator of PSD-95 postsynaptic targeting"; Neuron, Vol. 24, 659-672, Nov. 1999; Cell Press	
	W	DeSTROOPER, ET AL.; "Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's Disease-associated Presenilins"; Vol. 272, No. 6, February 27, 1997; pp. 3590-3598; The American Society for Biochemistry and Molecular Biology, Inc.	
	X	AOKI, ET AL.; "The novel protein-tyrosine phosphatase PTP20 is a positive regulator of PC12 Cell Neuronal Differentiation"; Vol. 271, No. 46, November 15, 1996, pp. 28422-29426; The American Society for Biochemistry and Molecular Biology, Inc.	
Y	WASIAK, ET AL.; "The Ras/Rac Guanine Nucleotide Exchange Factor Mammalian Son-of-sevenless Interacts with PACSIN 1/Syndapin I, a Regulator of Endocytosis and the Actin Cytoskeleton"; The Journal of Biological Chemistry; Vol.276, No. 28, July 13, pp. 26622-26628, 2001; The American Society for Biochemistry and Molecular Biology, Inc.		

Examiner Signature	J. Goedberg	Date Considered	7/7/03
--------------------	-------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/088 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known

Application Number	09/807,506
Filing Date	Int. Appl.: 10/10/1999 08/08/2001
First Named Inventor	Blumenfeld, et al.
Group Art Unit	
Examiner Name	Unassigned
Attorney Docket Number	50.US3.PCT

RECEIVED

HEALTH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
JG	Z	MARGOLIS, ET AL.; "cDNAs with long CAG trinucleotide repeats from human brain"; Hum Genet (1997) 100:11-122; Springer-Verlag 1997	
	AA	WEINBERGER, ET AL.; "Neurobiology of Schizophrenia and the Role of Atypical Antipsychotics - Prefrontal Neurons and the Genetics of Schizophrenia"; Biol Psychiatry 2001; 50:825-844; Society of Biological Psychiatry; 0006-3223/01; PII S0006-3223(01)01262-5	
	AB	BRANT, ET AL.; "Linkage Heterogeneity for the IBD1 Locus in Crohn's Disease Pedigrees by Disease Onset and Severity"; Gastroenterology 2000; 119:1483-1490; the American Gastroenterological Association 0016-5085/00	
	AC	WRIGHT, ET AL.; "Schizophrenia and HLA: a review"; Schizophrenia Research 47 (2001) 1-12; 0920-9964/01; Elsevier Science B.V.; PII: S0920-9964 (00) 00022-0	
	AD	KASHIMA, ET AL.; "Role of Unique Consecutive Glutamine Repeats in Active Murine Interleukin-2 Molecule"; J. Biochem, 102, 725-732 (1987)	
	AE	Accession: B75361; Adams, et al.; "Use of BAC End Sequences for Sequence-Ready Map Building"; Unpublished; XP-002135179	
	AF	Assession: AA989298; NCI-CGAP http://222.ncbi.nlm.nih.gov/ncicgap ; "National Cancer Institute, Cancer Genome Anatomy Project (CGAP) Tumor Gene Index"; Unpublished; XP-002135005	
	AG	Accession: L10374; Li, et al.; "Novel triplet repeat containing genes in human brain: cloning, expression, and length polymorphisms"; Genomics 18:572-579 (1993); XP-002134451	
	AH	WANG, ET AL.; "Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome"; www.sciencemag.org; Science, Vol. 280, May 15, 1998; pp. 10771082; XP-002089388	
	AI	KRUGLYAK, L.; "The use of a genetic map of biallelic markers in linkage studies"; nature genetics, Vol. 17, September 1997, pp. 21-24; XP-002050647	
↓	AJ	NYLANDER, ET AL.; "Anticipation in Swedish families with bipolar affective disorder"; J. Med. Genet. 1994; 31:686-689	

Examiner Signature	<i>G. Goldberg</i>	Date Considered	7/7/03
--------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/088 (10-01)
Approved for use through 10/31/2002. OMB 0657-0004
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED

MAY 16 2002

ENTER 1600/2900

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(use as many sheets as necessary)			
Sheet	5	of	5
		Application Number	09/807,506
		Filing Date	Int. Appl.: 10/10/1999 (06/04/2001)
		First Named Inventor	Blumenfeld, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	50.US3.PCT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AK	BASSETT, ET AL.; "Evidence for Anticipation in Schizophrenia"; Am. J. Hum. Genet. 54:864-870, 1994; The American Society of Human Genetics; 0002-9297/94/5405-0016	
	AL	PERUTZ, M.F.; "Glutamine repeats and inherited neurodegenerative diseases: molecular aspects; pp. 848-858; Current Opinion in Structural Biology, 1996, 6:848-858; Current Biology Ltd. ISSN 0959-440X	
	AM	STRAUB, ET AL.; "Genome scan for schizophrenia genes: a detailed progress report in an Irish cohort"; Abstracts	
	AN	PubMed Search for articles for "enzyme linked immunosorbent assay"; copy of page 1 of 3,307 pages, showing items 1-20 out of 66,134 National Library of Medicine	

Examiner Signature		Date Considered	7/7/03
--------------------	--	-----------------	--------

¹EXAMINER: Initial if reference considered, whether or not citations in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+